Biocon’s Insulin Glargine launched in Japan

Biocon announced that close on the heels of receiving approval for its Insulin Glargine from the Japanese regulator last quarter, its partner FUJIFILM Pharma (FFP) has launched the product in Japan today


Insulin Glargine BS Injection Kit (FFP) has been developed & manufactured by Biocon, and is being commercialized by FFP in Japan.

The product is a ready-to-use, prefilled disposable pen with 3 ml of 100IU Insulin Glargine.

It will provide a high quality, yet affordable, world-class long-acting biosimilar basal Insulin Glargine for patients of diabetes in Japan.

There were 7.2 million people with diabetes in Japan in 2015, according to the International Diabetes Federation.

The company through its partner aims to capture a significant share of the Japanese Glargine market of USD 144 million, which is the second largest market outside of North America & Europe, and is largely dominated by disposable pens.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email